Chris Proffitt

3.2k total citations
12 papers, 1.7k citations indexed

About

Chris Proffitt is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Chris Proffitt has authored 12 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 4 papers in Oncology and 3 papers in Organic Chemistry. Recurrent topics in Chris Proffitt's work include RNA modifications and cancer (4 papers), RNA and protein synthesis mechanisms (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Chris Proffitt is often cited by papers focused on RNA modifications and cancer (4 papers), RNA and protein synthesis mechanisms (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Chris Proffitt collaborates with scholars based in United States, Australia and Japan. Chris Proffitt's co-authors include Sean O’Brien, Kenna Anderes, Denis Drygin, Adam Siddiqui-Jain, William G. Rice, Caroline B. Ho, Josh Bliesath, Michael K. Schwaebe, David M. Ryckman and Mayuko Omori and has published in prestigious journals such as Blood, Cancer Research and Biochemical and Biophysical Research Communications.

In The Last Decade

Chris Proffitt

11 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chris Proffitt United States	7	1.4k	362	140	116	81	12	1.7k
Josh Bliesath United States	6	1.3k 0.9×	284 0.8×	109 0.8×	106 0.9×	59 0.7×	13	1.5k
Nicole Streiner United States	9	1.1k 0.8×	312 0.9×	105 0.8×	159 1.4×	75 0.9×	16	1.4k
Caroline B. Ho United States	10	1.6k 1.1×	405 1.1×	147 1.1×	167 1.4×	128 1.6×	15	1.9k
Nanni Huser United States	8	737 0.5×	238 0.7×	84 0.6×	79 0.7×	82 1.0×	15	999
Vishal Pendharkar Singapore	12	714 0.5×	270 0.7×	67 0.5×	137 1.2×	59 0.7×	15	1.0k
Sean Caenepeel United States	16	817 0.6×	433 1.2×	145 1.0×	77 0.7×	74 0.9×	22	1.3k
Kevin Hudson United Kingdom	17	779 0.6×	223 0.6×	156 1.1×	132 1.1×	53 0.7×	30	1.1k
Kenna Anderes United States	18	1.8k 1.3×	576 1.6×	218 1.6×	210 1.8×	134 1.7×	46	2.3k
Michael Zinda United States	22	935 0.7×	469 1.3×	188 1.3×	128 1.1×	135 1.7×	37	1.4k
Cem Elbi United States	23	1.4k 1.0×	462 1.3×	219 1.6×	58 0.5×	84 1.0×	38	2.2k

Countries citing papers authored by Chris Proffitt

Since Specialization

Citations

This map shows the geographic impact of Chris Proffitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chris Proffitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chris Proffitt more than expected).

Fields of papers citing papers by Chris Proffitt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chris Proffitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chris Proffitt. The network helps show where Chris Proffitt may publish in the future.

Co-authorship network of co-authors of Chris Proffitt

This figure shows the co-authorship network connecting the top 25 collaborators of Chris Proffitt. A scholar is included among the top collaborators of Chris Proffitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chris Proffitt. Chris Proffitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Grimshaw, Charles E., et al.. (2020). Biochemical and Cellular Profile of NIK Inhibitors with Long Residence Times. SLAS DISCOVERY. 26(5). 676–683.

Siddiqui-Jain, Adam, Joshua Bliesath, Mayuko Omori, et al.. (2012). CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy. Molecular Cancer Therapeutics. 11(4). 994–1005. 86 indexed citations

Bliesath, Joshua, Nanni Huser, Mayuko Omori, et al.. (2012). Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer Letters. 322(1). 113–118. 59 indexed citations

Haddach, Mustapha, Michael K. Schwaebe, Jerome Michaux, et al.. (2012). Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics. ACS Medicinal Chemistry Letters. 3(7). 602–606. 114 indexed citations

Drygin, Denis, Caroline B. Ho, Mayuko Omori, et al.. (2011). Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer. Biochemical and Biophysical Research Communications. 415(1). 163–167. 57 indexed citations

Drygin, Denis, Caroline B. Ho, Josh Bliesath, et al.. (2011). Abstract 4511: CX-5461, a non-genotoxic activator of p53 through selective inhibition of RNA polymerase I for the treatment of hematological cancers. Cancer Research. 71(8_Supplement). 4511–4511. 1 indexed citations

Drygin, Denis, Amy Lin, Josh Bliesath, et al.. (2010). Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth. Cancer Research. 71(4). 1418–1430. 462 indexed citations

Siddiqui-Jain, Adam, Denis Drygin, Nicole Streiner, et al.. (2010). CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy. Cancer Research. 70(24). 10288–10298. 421 indexed citations

Ho, Caroline B., Rachel Rice, Denis Drygin, et al.. (2010). CX-4945, a Selective and Orally Bioavailable Inhibitor of Protein Kinase CK2 Inhibits PI3K/Akt, JAK-STAT and NF-κB Signaling and Induces Apoptosis In Multiple Myeloma Cells. Blood. 116(21). 787–787. 3 indexed citations

10.

Drygin, Denis, Adam Siddiqui-Jain, Sean O’Brien, et al.. (2009). Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis. Cancer Research. 69(19). 7653–7661. 462 indexed citations

11.

Drygin, Denis, Josh Bliesath, Caroline B. Ho, et al.. (2009). Abstract C198: CX-4945, a novel small molecule inhibitor of CK2 protein kinase, reduces hyperactivated Akt signaling and synergizes with Akt inhibitors in breast cancer cells. Molecular Cancer Therapeutics. 8(12_Supplement). C198–C198. 1 indexed citations

12.

Drygin, Denis, Amanda Lin, Mustapha Haddach, et al.. (2008). 341 POSTER CX-5461, a novel, orally bioavailable selective small molecule inhibitor of RNA polymerase I transcription, induces autophagy and shows potent antitumor activity. European Journal of Cancer Supplements. 6(12). 108–108. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact